Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

Cancer Biotherapy and Radiopharmaceuticals

Volumn 16, Issue 5, 2001, Pages 359-370

  Solorzano, Carmen C ^b   Baker, Cheryl H ^a   Bruns, Christiane J ^a   Killion, Jerald J ^a   Ellis, Lee M ^b   Wood, Jeanette ^c   Fidler, Isaiah J ^a  

^a Departments of Cancer Biology   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Endothelial cell apoptosis; Pancreatic cancer; Tyrosine kinase inhibitor; VEGF VPF receptor

Indexed keywords

GEMCITABINE; PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; HUMAN CELL; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DEOXYCYTIDINE; ENZYME INHIBITORS; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PHTHALAZINES; PROLIFERATING CELL NUCLEAR ANTIGEN; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035217589     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497801753354267     Document Type: Article

References (47)

1. Pancreatic carcinoma
2. Cancer of the pancreas
3. Pancreatic carcinoma in perspective: A continuing challenge
4. Cancer statistics, 1999
5. Trends in pancreatic cancer mortality in Europe, 1955-1989
6. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
7. Angiogenesis in cancer, vascular, rheumatoid and other disease
8. Angiogenic factors
9. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
10. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas
11. The implications of angiogenesis for the biology and therapy of cancer metastasis
12. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
13. Vascular endothelial growth factor (VEGF) and its receptors
14. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
15. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
16. Vascular endothelial growth factor is a secreted angiogenic mitogen
17. Regulation of distinct steps of angiogenesis by different angiogenic molecules
18. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
19. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
20. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
21. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
22. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
23. Failure of blood-island formation and vasculogenesis in Flk-l-deficient mice
24. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
25. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
26. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer
27. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121
28. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
29. Prognostic significance of angiogenesis in human pancreatic cancer
30. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
31. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer
32. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
33. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
34. Monoclonal antibodies targeting the VEGF receptor-2 (Flkl/KDR) as an anti-angiogenic therapeutic strategy
35. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
36. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
37. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
38. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
39. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
40. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
41. Inhibiton of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases
42. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation
43. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice
44. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium
45. Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol
46. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
47. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro